Search Bar & Filters
Found 33 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of duvakitug in people with moderately to severely active Ulcerative Colitis UC. This Phase 3, multicenter, randomized, double-blind, placebo-controlled maintenance study aims to understand how well duvakitug works to maintain clinical remission and improve symptoms in participants with UC. The trial is sponsored by Sanofi and includes a large, diverse participant group aged 16 to 80 years. Participants receive subcutaneous injections of either one of three doses of duvakitug or a placebo following the study protocol. The study consists of two main periods a 40-week Pivotal Maintenance Sub-Study and a 240-week Open-Label Extension OLE Sub-Study. Those who do not join the OLE will complete a 45-day follow-up after the maintenance phase. Across both periods, participants may have up to 32 on-site visits to monitor treatment and health status. During the study, participants will undergo various assessments including endoscopy, clinical response evaluations, and symptom scoring by modified Mayo Score. Researchers will monitor clinical remission, endoscopic and histologic improvements, corticosteroid use, fatigue, abdominal pain, quality of life, and hospitalization incidence. Safety will be closely tracked through adverse event reporting and measurement of drug concentration and immune response. The total participation duration can be up to 286 weeks, allowing long-term monitoring of duvakitugs effects.
Actively Recruiting
Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are studying the effects and safety of different doses of the investigational drug NNC0662-0419 in adults living with type 2 diabetes. This study compares NNC0662-0419 to semaglutide, an approved treatment for type 2 diabetes, and a placebo. The purpose is to find out if NNC0662-0419 is effective and safe for treating this condition. Participants will receive one of the three treatments NNC0662-0419, semaglutide, or placebo, all given as weekly injections under the skin. The dose of NNC0662-0419 will be gradually increased over time. The study uses a randomized design where the treatment assignment is by chance, and both participants and researchers do not know the group assignments. Throughout the study, participants will attend visits and undergo assessments at various weeks up to week 48. Researchers will measure blood sugar control using glycated hemoglobin HbA1c at weeks 16, 28, and 40, as well as body weight, blood glucose levels, cholesterol, kidney function, and other health markers. Safety will be monitored by recording any adverse events. The total study participation will last several months with regular monitoring.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a drug called brenipatide when added to standard treatment for adults with major depressive disorder. The study compares brenipatide plus standard care to a placebo plus standard care to see if it can delay the return of major depressive symptoms. This is a phase 3, randomized, double-blind trial sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all given by subcutaneous injection along with their standard care. The study has four periods a screening phase lasting about one month, a combined treatment and post-treatment phase lasting at least 12 months, and a safety follow-up period of about two months. The total participation time may vary and can be shortened if symptoms worsen or if participants withdraw. During the study, participants will self-inject the study medication and keep electronic and paper diaries, complete questionnaires, and attend scheduled visits. Researchers will measure the time to relapse of major depressive disorder symptoms as the main outcome. Other assessments include changes in body weight, depression severity, functional impairment, anxiety levels, quality of life, and presence of treatment-related antibodies. Safety monitoring will continue throughout the study and follow-up periods.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.
Actively Recruiting
Researchers are evaluating eloralintide, a drug given by injection, for its effects on body weight reduction in adults who are overweight or have obesity along with type 2 diabetes. The study aims to compare eloralintide with a placebo to assess its safety and effectiveness. Participation will last approximately 75 weeks, providing a thorough evaluation period. Participants will be randomly assigned to receive one of four different doses of eloralintide or a placebo, all administered by subcutaneous injection once weekly. This phase 3, double-blind study ensures that neither participants nor researchers know which treatment is given, maintaining unbiased results. The treatment period lasts up to 64 weeks, with ongoing monitoring throughout. During the study, participants will have regular visits to assess changes in body weight, body fat, waist size, blood sugar control HbA1c, blood pressure, and other health markers. Questionnaires about physical function, eating behavior, and quality of life will also be collected. Safety will be monitored continuously, and the main measurement is the percent change in body weight at week 64 compared to the start. Participants involvement will last about 75 weeks in total.
Actively Recruiting
Researchers are evaluating the efficacy and safety of eloralintide in adults with moderate-to-severe obstructive sleep apnea OSA who are also obese or overweight. The study uses a master protocol called YDAO that includes two separate studies YSA1 for participants who cannot or do not want to use Positive Airway Pressure PAP therapy, and YSA2 for those who have been on PAP therapy for at least three months and plan to continue it during the study. The goal is to understand how eloralintide affects body weight and sleep apnea severity. Participants will be randomly assigned to receive either eloralintide or a placebo, both given as weekly subcutaneous injections. The study lasts about 76 weeks and includes two groups based on PAP therapy use. During the study, participants will continue their current PAP therapy status according to their assigned group. The study is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the study, participants will undergo assessments at baseline and Week 64, including measuring changes in body weight, apnea-hypopnea index AHI, blood pressure, triglycerides, sleep-related impairment, and other health markers. Researchers will also monitor safety, medication use, and pharmacokinetics. Participants can expect regular visits for evaluations and monitoring over the study period to understand the effects of eloralintide on OSA and obesity-related health factors.
Actively Recruiting
Researchers are studying the effectiveness and safety of a combination drug called eloralintide and tirzepatide EloraTZP compared to tirzepatide alone for reducing body weight in adults who have obesity or are overweight and also have type 2 diabetes. This Phase 3 trial aims to understand how these treatments affect weight loss and other health measures over time. Participants will be randomly assigned to receive either EloraTZP or tirzepatide, both given by subcutaneous injection. The study involves a double-blind design, meaning neither participants nor researchers know which treatment is given. The treatment period lasts for about 100 weeks, during which participants receive regular doses and monitoring. During the study, participants will have their body weight and other health indicators, such as waist circumference, blood sugar levels, blood pressure, cholesterol, and quality of life, regularly measured from the start through week 100. Researchers will also monitor safety through laboratory tests and pharmacokinetic assessments. Overall participation in the study lasts about two years, with ongoing evaluations to understand the treatments effects and safety.
1-10 of 33
1